These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 35716252)

  • 1. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
    Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
    Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
    PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
    Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
    Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
    Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
    JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
    Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
    Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK gene fusion testing and management in lung cancer.
    Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
    Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland.
    Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J
    Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
    Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
    Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan.
    Nakata E; Osone T; Ogawa T; Taguchi T; Hattori K; Kohsaka S
    Cancer Med; 2024 Jun; 13(12):e7351. PubMed ID: 38925616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTRK fusions in thyroid cancer: Pathology and clinical aspects.
    Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X
    Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.